Hepatitis B virus infection in hemodialysis populations: progress toward prevention | Zendy

Katherine A. Barraclough | Zendy; E. Geoffrey Playford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hepatitis B virus infection in hemodialysis populations: progress toward prevention

Author(s) -

Katherine A. Barraclough,

E. Geoffrey Playford

Publication year - 2010

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2009.456

Subject(s) - seroconversion , medicine , hemodialysis , hepatitis b virus , adjuvant , immunology , hepatitis b vaccine , hepatitis b , kidney disease , vaccination , virology , virus , hbsag

Hemodialysis patients are at increased risk of acquiring hepatitis B virus (HBV) infection. Administration of the standard HBV vaccine is suboptimal as a means of prevention because of an impaired seroconversion response in individuals with chronic kidney disease. Surquin and colleagues describe a novel vaccine adjuvant system that increases speed of seroconversion and duration of seroprotection compared with older vaccine formulations. However, its ability to improve overall seroconversion response remains unproven.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research